Condition: Glaucoma, Open-Angle · Sponsor: Mankind Pharma Limited
This is a randomized, double-masked, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost Ophthalmic Solution, 0.01% of Mankind Pharma Limited, India Reference Product - LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% of Allergan, Inc.,
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| CBCC Global Research Site:011 | Bakersfield, California, United States | — |
| CBCC Global Research Site 016 | Mission Hills, California, United States | — |
| CBCC Global Research Site 017 | Newport Beach, California, United States | — |
| CBCC Global Research Site: 012 | Newport Beach, California, United States | — |
| CBCC Global Research Site 013 | Pasadena, California, United States | — |
| CBCC Global Research Site 019 | Petaluma, California, United States | — |
| CBCC Global Research Site 015 | San Diego, California, United States | — |
| CBCC Global Research Site 020 | Pembroke Pines, Florida, United States | — |
| CBCC Global Research Site 018 | Houston, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04890106